Novel hydroxymethyl- and alkoxymethyl-oxazolidinone compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.
本发明揭示了新型羟甲基和烷氧基
噁唑啉酮化合物及其药学上可接受的盐。还描述了这些化合物的合成以及它们作为α1a
肾上腺素能受体拮抗剂的用途。这些化合物的一个应用是治疗良性前列腺增生症。这些化合物在其选择性方面表现出能够放松富含α1a受体亚型的平滑肌组织的能力,而不同时引起低血压。这样的组织包括围绕尿道内衬的组织。因此,本发明化合物的一个用途是通过允许尿液流动更少地受阻,为患有良性前列腺增生症的男性提供急性缓解。本发明化合物的另一个用途是与人类5α-还原酶
抑制剂化合物结合,从而可以实现良性前列腺增生症的急性和慢性缓解。